The upcoming coronavirus vaccination offers, in addition to hopes for an early resolution of the crisis, a chance for great wealth. So to some. This is confirmed by the recent change in the ranking of the 500 richest people in the world, as monitored by the Bloomberg agency. At the end of the week, the co-founder of the German company BioNTech Ugur Sahin also appeared in it for the first time. This happened after the United Kingdom allowed the use of a vaccine, which BioNTech developed together with the American company Pfizer, and stock exchange investors subsequently pushed the shares of the German company to a historical record.
–
BioNTech has already increased its value by more than 250 percent over the last year. Now one of the company’s securities is trading for about $ 118, which means that the stock strengthened by about ten percent this week alone.
Rising stock prices make Sahin the 493rd richest man on the planet with a net worth of around $ 5.1 billion, writes Bloomberg. In terms of crowns, Sahin has assets worth about 111 billion.
–
–
The United Kingdom is the first country in the West to allow the use of a coronavirus vaccine. However, the vaccine is still awaiting approval by the US and EU authorities with 95% effectiveness.
The German company used to focus on the fight against cancer. In January, however, Sahin and his wife and co-worker Özl Türecio decided to turn their attention to a new type of SARS-CoV-2 virus. Their result is a confirmation of the functionality of a new type of drug, the development of which they have been dealing with throughout their careers. “It can open up the pharmaceutical market for completely new types of molecules,” Sahin said.
–
–
The Turkish-born Sahin, who now holds 18 percent of BioNTech, has joined the Struengmann brothers, who have made it to the richest people before. Both control a total of half of BionTech’s shares and their combined wealth is estimated at $ 24 billion.
However, the closely watched race for the first “western” vaccine helped with the growth of stocks and competition. The value of Moderna, which has also completed testing, has grown by more than 700 percent this year. As a result, the company’s original investors became dollar billionaires. These include Bob Langer, a professor at the Massachusetts Institute of Technology, Tim Springer, a professor at Harvard, and the head of Moderna, Stephane Bancel.
– .
